The Side Effects of Tirzepatide for Weight Loss, Explained Honestly

Step 1: What happens in your first few weeks on tirzepatide

The starter dose of 2.5 mg exists to let your system adjust, not to drive weight loss from day one. Even so, some people notice nausea within hours of their first injection. This is normal. Tirzepatide side effects like nausea arise because the medicine slows how quickly food leaves your stomach, a mechanism that reduces hunger but can also make you feel queasy, full after small amounts, or occasionally sick. Diarrhoea, constipation, indigestion and burping are also common early on.

Most people find these effects peak in the first day or two after each injection, then settle. Keeping meals smaller and lower in fat during this period helps. Drinking enough water matters too, because vomiting or diarrhoea can dehydrate you faster than you expect. If you store your pen in the fridge door alongside other weekly essentials, injecting at a regular time each week (same day, same routine) reduces the chance of forgetting a dose and then doubling up accidentally.

Headache, fatigue and dizziness can also appear early, often as your calorie intake shifts downward. These are generally short-lived. A more detailed breakdown of Mounjaro's full side-effect profile covers how often each effect was recorded in the clinical programme.

Step 2: What changes when you move to a higher dose

Tirzepatide is titrated in 2.5 mg steps, each increase restarts the adjustment window. Someone who sailed through 2.5 mg may find 5 mg or 7.5 mg briefly unsettled their stomach again. This is the normal pattern, not evidence that treatment has failed or that you are intolerant.

Injection-site reactions are worth mentioning here: redness, mild swelling or itching at the site of the injection can appear with any dose. Rotating between your abdomen, thigh and upper arm reduces this. If a weal or lump persists for more than a few days, or if redness spreads beyond the injection site, tell your prescriber.

Some people notice hair thinning a few months into treatment. Rapid weight loss of any kind can trigger a temporary phase of hair shedding called telogen effluvium; it tends to resolve without treatment but is worth raising with your prescriber if it concerns you. You can read more about the longer-term side effects of tirzepatide for a fuller picture of what the evidence shows beyond the first few months.

Step 3: Serious effects, recognise these and act promptly

Rare effects can be serious. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known, infrequent but potentially severe risk with GLP-1 medicines including tirzepatide. The symptom to recognise is severe, persistent pain in your stomach that may radiate through to your back, sometimes with vomiting. This is not ordinary nausea. If you develop it, stop eating and drinking and seek urgent medical help, call 111 or go to A&E depending on severity.

Other effects that need prompt medical attention include: signs of a serious allergic reaction (swelling of the face, lips, throat or tongue; difficulty breathing; a rapid or pounding heartbeat); symptoms of severe dehydration from prolonged vomiting or diarrhoea (extreme thirst, dark urine, very little urine, confusion); and gallbladder problems such as upper-right abdominal pain, fever or jaundice.

If you experience thoughts of self-harm or a significant low mood change after starting treatment, speak to your GP or call 111. This is listed as a possible effect and should always be taken seriously. The MHRA's Yellow Card scheme lets patients report any suspected side effects directly, your report contributes to ongoing safety monitoring for all users of these medicines.

For a broader look at the overall safety evidence, this page on how safe tirzepatide is for weight loss covers the clinical trial safety data in context.

Who is most likely to need extra care

Tirzepatide is not suitable for everyone, and some health histories change the risk picture meaningfully. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is a contraindication listed in the SmPC. A history of pancreatitis, or certain gastrointestinal conditions, requires careful prescriber assessment before starting. Tirzepatide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive.

Women taking oral contraceptives should add a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because Mounjaro side effects include changes to gastric emptying that can reduce how much of the pill is absorbed. This is set out in NHS England's guidance on weight-management injections and is one of the things our prescribers discuss as standard.

If you are not sure whether your medical history affects your suitability, this page on Mounjaro's safety profile goes through the key contraindications and cautions in plain language. Our prescribers review every consultation personally before any treatment is approved, check your eligibility to start that conversation.